FA
MRK icon

Fagan Associates’s Merck MRK Stock Holding History

Fagan Associates’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Sell
2,075
-43
-2% -$4.96K 0.03% 122
2025
Q4 		$223K Buy
+2,118
New +$199K 0.03% 127
2025
Q2 		– Sell
-2,597
Closed -$233K – 133
2025
Q1 		$233K Buy
2,597
+200
+8% +$18.7K 0.04% 115
2024
Q4 		$238K Hold
2,397
– – 0.04% 123
2024
Q3 		$272K Sell
2,397
-98
-4% -$11.6K 0.05% 117
2024
Q2 		$309K Hold
2,495
– – 0.05% 105
2024
Q1 		$329K Buy
2,495
+100
+4% +$12.3K 0.06% 105
2023
Q4 		$261K Sell
2,395
-100
-4% -$10.4K 0.06% 103
2023
Q3 		$257K Buy
2,495
+75
+3% +$8.08K 0.06% 103
2023
Q2 		$279K Buy
2,420
+68
+3% +$7.72K 0.07% 100
2023
Q1 		$250K Hold
2,352
– – 0.06% 112
2022
Q4 		$261K Hold
2,352
– – 0.07% 109
2022
Q3 		$203K Hold
2,352
– – 0.06% 116
2022
Q2 		$214K Buy
+2,352
New +$209K 0.06% 115

Other funds holding MRK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fagan Associates's MRK Position: Q1 2026 in Review

Fagan Associates reduced its Merck (MRK) stake by 2% in Q1 2026, selling an estimated $4.96K and leaving 2,075 shares worth $250K. The position accounts for 0.03% of the portfolio, ranked #122.

Fagan Associates first reported a position in MRK in Q2 2022 and has held it in 14 quarters since. The position peaked at $329K in Q1 2024. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Fagan Associates held 2,075 shares of Merck worth $250K as of Q1 2026.
  • Fagan Associates sold 43 Merck shares in Q1 2026, an estimated $4.96K.
  • Merck made up 0.03% of Fagan Associates's portfolio in Q1 2026, its #122 holding.
  • Fagan Associates first reported a position in Merck in Q2 2022 and has held it in 14 quarters since.
  • Fagan Associates's Merck position peaked at $329K in Q1 2024.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Fagan Associates's 13F filing for Q1 2026, filed 4 May 2026.